No Data
shenzhen salubris pharmaceuticals (002294.SZ): plans to increase capital by 30 million yuan for Purui Benchmark.
On November 22, Gelonghui reported that shenzhen salubris pharmaceuticals (002294.SZ) announced that according to the company's global strategy development plan, shenzhen salubris pharmaceuticals plans to increase its capital investment in the company puri benchmark technology (peking) limited (hereinafter referred to as "puri benchmark" or "symbol company") with self-raised funds of 30 million yuan to acquire 3.2154% of puri benchmark's shares. After the completion of this capital increase, the company will directly hold 8.5745% of puri benchmark's shares. Prior to the capital increase, the company and its subsidiary holding enterprise ningbo meishan bonded port area wosheng jingjia private equity partnership (limited partnership) (hereinafter referred to as "wosheng jingjia").
Express News | 2024 National Congress second day begins: shenzhen salubris pharmaceuticals, haisco pharmaceutical group, jiangsu hengrui pharmaceuticals are the first batch to enter. Concentrated appearance of diabetes drugs.
Shenzhen Salubris Pharmaceuticals (002294): Significant improvement in performance in the third quarter, innovative prospects ahead.
Event company releases the Q3 report for 2024: In the first three quarters of 2024, the company achieved revenue of 3.001 billion yuan, a year-on-year increase of 22.18%, with a net income attributable to shareholders of the listed company, deducting non-recurring gains and losses, of 4.9.
Express News | Favoring high-quality assets, social security funds appeared in the shareholder list of 37 companies in the third quarter report.
Shenzhen Salubris Pharmaceuticals to Increase Capital of US Subsidiary by About 350 Million Yuan
Shenzhen Salubris Pharmaceuticals (002294): Innovative products gradually increase in volume. Smooth progress in product research and development.
Event: In the first three quarters of 2024, the company achieved revenue of 3.001 billion yuan, a year-on-year increase of 22.18%; achieved non-net profit attributable to the parent company of 0.497 billion yuan, a year-on-year increase of 14.94%; in the third quarter of 2024, the com
No Data
No Data